//fpnotebook.com/
Intraocular Carbonic Anhydrase Inhibitor
Aka: Intraocular Carbonic Anhydrase Inhibitor, Dorzolamide, Trusopt, Brinzolamide, Azopt
- Indication
- Open Angle Glaucoma
- Patients unable to tolerate Beta Blocker or as adjunct
- Mechanism
- Inhibits bicarbonate formation in the ciliary body
- Results in decreased aqueous production
- Preparations
- Topical
- Dorzolamide (Trusopt) 2%, 1 drop three times daily
- Brinzolamide (Azopt) 1%, 1 drop three times daily
- Available as combination with Brimonidine (Simbrinza)
- Systemic
- Acetazolamide (Diamox)
- Methazolamide (Neptazane)
- Efficacy
- Less effective than Intraocular Beta Blocker and Intraocular Prostaglandin
- Adverse Effects
- Topical is well tolerated (contrast with oral)
- May cause bitter taste
- Systemic
- Paresthesias in hands and face
- Malaise, Anorexia, and severe weight loss
- Hypokalemia
- Nephrolithiasis
- Reference
- (1995) Med Lett Drugs Ther 37:(956):76-77 [PubMed]